Announced by Sanofi on May 10, 2024, the updated FDA label is based on full results from the pivotal phase 3 XTEND-Kids study.
Hemophilia Reports - June 2024
An analysis of an FDA adverse event database found thrombotic adverse events were more frequently reported with emicizumab than those of FVIII products.
Patients in France with hemophilia A who switched their FVIII replacement treatment trended towards fewer bleeding events and articular non-bleeding events requiring hospitalization.
Presented at ASH 2023, a new study demonstrated physical activity does not increase bleeding for patients with hemophilia A as patients with low physical activity still experienced frequent bleeding.
Advertisement
Advertisement
Trending on HCPLive
1
Navigating Emotional Burden in IBD
2
Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD
3
Open Communication Between Patients and Providers in IBD
4
Linaclotide in Pediatric IBS-C—Evidence, Indications, and Practical Use
5